These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 7207885

  • 1. Chelation therapy for iron overload.
    Nutr Rev; 1980 May; 38(5):185-7. PubMed ID: 7207885
    [No Abstract] [Full Text] [Related]

  • 2. Iron metabolism and chelation therapy in hemosiderosis.
    Graziano JH.
    Curr Top Hematol; 1978 May; 1():127-50. PubMed ID: 400529
    [No Abstract] [Full Text] [Related]

  • 3. [Further experiences with iron-chelating therapy (desferrioxamine and ascorbic acid) in siderochromatosis and Cooley's disease].
    Cartei G, Cazzavillan M, Chisesi T, Battista R, Barbui T, Dini E.
    Minerva Med; 1978 Mar 17; 69(13):811-21. PubMed ID: 643223
    [No Abstract] [Full Text] [Related]

  • 4. [Guidelines for diagnosis and treatment of secondary iron overload in patients with congenital anemia].
    Cario H, Grosse R, Janssen G, Jarisch A, Meerpohl J, Strauss G, German hematology societies (GPOH and DGHO).
    Klin Padiatr; 2010 Nov 17; 222(6):399-406. PubMed ID: 20862634
    [Abstract] [Full Text] [Related]

  • 5. [Biologically active hydroxamic acids--iron complexons].
    Kol'tsova GN, Mel'nikovskaia NN, Likhodzievskiĭ KG, Rozenberg GIa.
    Gematol Transfuziol; 1984 Sep 17; 29(9):56-9. PubMed ID: 6394425
    [No Abstract] [Full Text] [Related]

  • 6. Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamine.
    Giardina PJ, Grady RW.
    Semin Hematol; 1995 Oct 17; 32(4):304-12. PubMed ID: 8560288
    [Abstract] [Full Text] [Related]

  • 7. Iron chelation in acute iron poisoning and chronic hypersiderosis.
    Walsh JR, Gillick JB.
    Clin Pediatr (Phila); 1965 Nov 17; 4(11):633-8. PubMed ID: 5844429
    [No Abstract] [Full Text] [Related]

  • 8. Iron chelation.
    Chandy M.
    J Assoc Physicians India; 1991 Sep 17; 39(9):665-6. PubMed ID: 1814896
    [No Abstract] [Full Text] [Related]

  • 9. Chronic iron overload: new chelators and new strategies.
    Fairbanks VF.
    J Lab Clin Med; 1978 Aug 17; 92(2):141-3. PubMed ID: 681806
    [No Abstract] [Full Text] [Related]

  • 10. [Effect of desferrioxamine B and 2-(beta-aminoethoxy)cyclohexylaminetetraacetate in experimental hemochromatosis in rats and in primary hemochromatosis of man].
    Bohne F, Lessmann J.
    Arzneimittelforschung; 1969 Jun 17; 19(6):944-7. PubMed ID: 5820039
    [No Abstract] [Full Text] [Related]

  • 11. [The treatment of post-transfusional hemochromatosis with chelating agents].
    Delvaux D, Andrien JM, Fillet G.
    Rev Med Liege; 1981 Jun 01; 36(11):477-80. PubMed ID: 6789438
    [No Abstract] [Full Text] [Related]

  • 12. [Use of desferal in treatment of sideroses of different origin. (Literature review)].
    Turbina NS.
    Probl Gematol Pereliv Krovi; 1968 Jul 01; 13(7):47-52. PubMed ID: 4898933
    [No Abstract] [Full Text] [Related]

  • 13. The treatment of hemosiderosis in thalassaemia major with desferrioxamine-B.
    Kirimlidis S, Philippidis P, Drossos C, Economidis J.
    Helv Paediatr Acta; 1966 Sep 01; 21(4):343-50. PubMed ID: 5997620
    [No Abstract] [Full Text] [Related]

  • 14. Clinical usefulness of iron chelating agents.
    Waxman HS, Brown EB.
    Prog Hematol; 1969 Sep 01; 6():338-73. PubMed ID: 4976246
    [No Abstract] [Full Text] [Related]

  • 15. [Specific treatment of excessive iron deposition in the tissues].
    Plachecka-Gutowska M, Mikolajew M.
    Pol Arch Med Wewn; 1965 Sep 01; 35(1):111-7. PubMed ID: 5900073
    [No Abstract] [Full Text] [Related]

  • 16. Iron chelation therapy in hereditary hemochromatosis and thalassemia intermedia: regulatory and non regulatory mechanisms of increased iron absorption.
    Kontoghiorghes GJ, Spyrou A, Kolnagou A.
    Hemoglobin; 2010 Jun 01; 34(3):251-64. PubMed ID: 20524815
    [Abstract] [Full Text] [Related]

  • 17. Desferrioxamine-chelatable iron (DCI), a component of serum non-transferrin-bound iron (NTBI) used for assessing iron chelation therapy.
    Breuer W, Ermers MJ, Pootrakul P, Abramov A, Hershko C, Cabantchik ZI.
    Transfus Sci; 2000 Dec 01; 23(3):241-2. PubMed ID: 11099901
    [No Abstract] [Full Text] [Related]

  • 18. [Myocardiopathy caused by iron deposition. Treatment with chelating agents].
    Rodríguez Reguero JJ, Iglesias Cubero G, Espolita Santos A, López de la Iglesia JM, Enríquez Martín J, Tomás Mauri J, López-Negrete L.
    Rev Esp Cardiol; 1985 Dec 01; 38(5):356-7. PubMed ID: 4081244
    [No Abstract] [Full Text] [Related]

  • 19. Iron overload: pathogenesis and treatment with chelating agents.
    Huebers H.
    Blut; 1983 Aug 01; 47(2):61-7. PubMed ID: 6871476
    [No Abstract] [Full Text] [Related]

  • 20. [Therapeutic results in the treatment of primary and secondary hemochromatoses with Desferal].
    Wöhler F.
    Blut; 1967 Apr 01; 15(1):33-42. PubMed ID: 6025965
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.